Stock Scorecard
Stock Summary for Novo Nordisk (NVO) - $126.16 as of 4/24/2024 8:56:23 PM EST
Total Score
13 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NVO
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NVO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NVO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for NVO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for NVO
Financial Details for NVO
Company Overview |
|
|---|---|
| Ticker | NVO |
| Company Name | Novo Nordisk |
| Country | USA |
| Description | Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 126.16 |
| Last Day Price Updated | 4/24/2024 8:56:23 PM EST |
| Last Day Volume | 3,092,010 |
| Average Daily Volume | 3,950,010 |
| 52-Week High | 137.57 |
| 52-Week Low | 74.92 |
| Last Price to 52 Week Low | 68.39% |
Valuation Measures |
|
| Trailing PE | 46.13 |
| Industry PE | 100.27 |
| Sector PE | 60.54 |
| 5-Year Average PE | 2.71 |
| Free Cash Flow Ratio | 39.06 |
| Industry Free Cash Flow Ratio | 12.60 |
| Sector Free Cash Flow Ratio | 30.19 |
| Current Ratio Most Recent Quarter | 0.82 |
| Total Cash Per Share | 3.23 |
| Book Value Per Share Most Recent Quarter | 23.90 |
| Price to Book Ratio | 36.21 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 2.43 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 4,461,530,000 |
| Market Capitalization | 562,866,624,800 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 3/22/2024 |
| Last Dividend Amount | 0.44 |
| Current Dividend Amount | 0.93 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 1.37 |
| Trailing Annual Dividend Yield | 1.10% |
| Forward Annual Dividend Rate | 1.56 |
| Forward Annual Dividend Yield | 1.25% |
| 5-Year Dividend Payments Count | 10 |
| 3-Year Average Dividend Yield | 1.16% |
| 5-Year Average Dividend Yield | 1.50% |
| 1-Year Dividend Growth Rate Percentage | 29.00% |
| 3-Year Dividend Growth Rate Percentage | 18.40% |
| 5-Year Dividend Growth Rate Percentage | 13.73% |
| All-Time Dividend Growth Rate Percentage | 18.10% |
| Dividend Payout Ratio | 51.76% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 63.10% |
| Annual Earnings Growth | 50.71% |
| Reported EPS 12 Trailing Months | 2.66 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 36.10 |
| Net Income Twelve Trailing Months | 83,683,000,000 |
| Net Income Past Year | 83,683,000,000 |
| Net Income Prior Year | 55,525,000,000 |
| Quarterly Revenue Growth YOY | 37.00% |
| 5-Year Revenue Growth | 15.74% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 14,392,000,000 |
| Total Cash Past Year | 14,392,000,000 |
| Total Cash Prior Year | 12,653,000,000 |
| Net Cash Position Most Recent Quarter | -1,584,000,000 |
| Net Cash Position Past Year | -1,584,000,000 |
| Long Term Debt Past Year | 15,976,000,000 |
| Long Term Debt Prior Year | 20,775,000,000 |
| Total Debt Most Recent Quarter | 15,976,000,000 |
| Equity to Debt Ratio Past Year | 0.87 |
| Equity to Debt Ratio Most Recent Quarter | 0.87 |
| Total Stockholder Equity Past Year | 106,561,000,000 |
| Total Stockholder Equity Prior Year | 83,486,000,000 |
| Total Stockholder Equity Most Recent Quarter | 106,561,000,000 |
Options |
|
| Put/Call Ratio | 0.70 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.47 |
| MACD Signal | 0.14 |
| 20-Day Bollinger Lower Band | 92.48 |
| 20-Day Bollinger Middle Band | 115.91 |
| 20-Day Bollinger Upper Band | 139.34 |
| Beta | 0.20 |
| RSI | 44.56 |
| 50-Day SMA | 99.00 |
| 200-Day SMA | 60.66 |
System |
|
| Modified | 4/23/2024 7:20:42 AM EST |